Although many next generation sequencing panels include FLT3, their performance in detecting FLT3-internal tandem duplication and their accuracy of assessing FLT3-internal tandem duplication allelic ratio for acute myeloid leukemia risk stratification has not been thoroughly examined in comparison with the standard fragment analysis assay. The gene discussed is FLT3; the disease is acute myeloid leukemia.